Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 604 trials

Macular Telangiectasia Type 1: Aflibercept vs. Placebo

We are studying whether aflibercept can improve retinal thickness and vision in patients with macular telangiectasia type 1 compared to a placebo. The trial also looks at the safety of the treatment.

Macular Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesOphthalmology

Knee Osteoarthritis: Intra-Articular Clodronate Study

We are investigating whether different doses of clodronate can help reduce knee pain and improve function in people with painful knee osteoarthritis. The study will also monitor safety and tolerability of the treatment.

Knee Osteoarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Dapagliflozin for Decompensated Liver Cirrhosis

We are studying whether dapagliflozin is safe and effective for patients with decompensated liver cirrhosis compared to standard treatments. The trial also looks at how it may affect quality of life and various health markers.

Decompensated Liver Cirrhosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Short Bowel Syndrome: Crofelemer Study

We are testing crofelemer to see if it helps adults with Short Bowel Syndrome and Intestinal Failure manage their symptoms better. The study will assess its safety and effectiveness compared to a placebo.

Short Bowel Syndrome and Intestinal Failure6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Inhaled Molgramostim for Pediatric Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

We are studying the effects of inhaled molgramostim in children and teens with aPAP. The goal is to see if it is safe and effective for improving their condition.

Pulmonary Alveolar Proteinosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsPulmonology

Haemophilia A: Efanesoctocog Alfa Treatment Study

We are investigating how efanesoctocog alfa affects joint health in patients with haemophilia A. The study aims to understand improvements in joint swelling and overall health during treatment.

Haemophilia A1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOrthopedics and Traumatology

Irritable Bowel Syndrome: Symbioflor®2 Treatment

We are studying an oral treatment with living bacteria for people with diarrhea-predominant irritable bowel syndrome (IBS-D). The goal is to see if it helps reduce symptoms compared to a placebo.

Irritable Bowel Syndrome6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementGastroenterology

Generalized Myasthenia Gravis: Telitacicept Study

We are testing a new treatment called telitacicept for people with generalized myasthenia gravis. The study aims to see if it works better than a placebo and to check its safety.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurologyRheumatology

Prostate Cancer: Darolutamide Addition Study

We are studying whether adding darolutamide to standard treatment helps men with metastatic castration-resistant prostate cancer live longer without cancer progression.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Burn Treatment in Children: New Skin Graft Study

We are testing a new skin graft made from the child's own cells for treating severe burns in children. The goal is to see if it works better and is safer than the standard skin graft method.

Children with Severe Burns1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatology

Advanced Solid Tumors: ORIC-114 Study

We are testing a new drug, ORIC-114, for patients with advanced solid tumors that have EGFR or HER2 alterations. The study will assess its safety and effectiveness alone and with chemotherapy.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Major Depressive Disorder: Liposom Forte with Citalopram

We are studying whether Liposom Forte can enhance and speed up the response to citalopram in elderly patients with Major Depressive Disorder. The trial also looks at the safety of this treatment.

Major Depression3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPsychiatry

Viral Infections After Stem Cell Transplant: Multispecific T-Cell Therapy

We are studying a new treatment using multispecific T-cells for patients with viral infections that resist chemotherapy after stem cell transplantation. The goal is to see if this therapy can improve symptoms and overall health.

Viral Infections After Stem Cell Transplant>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesHematologyInfectious DiseasesOncology

Amantadine for Improving Alertness in ICU Patients

We are studying whether Amantadine can enhance responsiveness in patients receiving intensive care. The trial will measure changes in alertness over several days using established clinical scoring systems.

Unresponsive Wakefulness Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Migraine Prevention in Kids: Rimegepant Study

We are testing a new medication, rimegepant, to see if it helps reduce migraine days in children and adolescents aged 6 to under 18. The study compares its effects to a placebo to understand its potential benefits.

Migraine≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Cardiac Surgery: Fibrinogen Concentrate Study

We are testing a new treatment to manage bleeding in patients undergoing complex cardiac surgery. The goal is to see if it reduces the need for blood transfusions compared to a placebo.

Functional Disturbances After Cardiac SurgeryBleeding in Cardiac Surgery Patients>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Hemolytic Uremic Syndrome: INM004 Treatment for Kids

We are studying a new treatment for children with Hemolytic Uremic Syndrome caused by E. coli to see if it helps improve kidney function and reduce complications. The trial will also evaluate the safety of this treatment.

Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesNephrologyPediatrics

Organ Transplantation: Custodiol-N vs. Custodiol Solution

We are studying a new preservation solution for kidney, liver, and pancreas transplants to see if it works as well as the current standard. This research may help improve outcomes for transplant recipients.

Organ Transplant Candidates>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyHepatologyInternal MedicineNephrologyOrthopedics and Traumatology

Buprenorphine for Severe Suicidal Thoughts in Major Depression

We are studying whether buprenorphine can help reduce severe suicidal ideas in individuals with major depressive episodes. The trial will compare different doses to find the most effective and safest option.

Clinical Depression≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPsychiatry

Psoriatic Arthritis: Guselkumab for Enthesitis

We are studying whether Guselkumab can help reduce inflammation in patients with psoriatic arthritis who have not received prior treatments. This trial focuses on those with ultrasound-confirmed enthesitis.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesRheumatology